200 related articles for article (PubMed ID: 34589390)
21. Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4
Cano-Garrido O; Álamo P; Sánchez-García L; Falgàs A; Sánchez-Chardi A; Serna N; Parladé E; Unzueta U; Roldán M; Voltà-Durán E; Casanova I; Villaverde A; Mangues R; Vázquez E
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208189
[TBL] [Abstract][Full Text] [Related]
22. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.
Stalmeijer EH; Van Rij RP; Boeser-Nunnink B; Visser JA; Naarding MA; Schols D; Schuitemaker H
J Virol; 2004 Mar; 78(6):2722-8. PubMed ID: 14990692
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.
Bader J; Däumer M; Schöni-Affolter F; Böni J; Gorgievski-Hrisoho M; Martinetti G; Thielen A; Klimkait T;
Clin Infect Dis; 2017 Feb; 64(3):295-300. PubMed ID: 27838645
[TBL] [Abstract][Full Text] [Related]
24. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
[TBL] [Abstract][Full Text] [Related]
25. EPI-X4, a novel endogenous antagonist of CXCR4.
Buske C; Kirchhoff F; Münch J
Oncotarget; 2015 Nov; 6(34):35137-8. PubMed ID: 26459389
[No Abstract] [Full Text] [Related]
26. Dimerization of the Peptide CXCR4-Antagonist on Macromolecular and Supramolecular Protraction Arms Affords Increased Potency and Enhanced Plasma Stability.
Harms M; Hansson RF; Carmali S; Almeida-Hernández Y; Sanchez-Garcia E; Münch J; Zelikin AN
Bioconjug Chem; 2022 Apr; 33(4):594-607. PubMed ID: 35293739
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj RT; Bridger GJ; Kaller A; McEachern EJ; Crawford JB; Zhou Y; Atsma B; Langille J; Nan S; Veale D; Wilson T; Harwig C; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Apr; 53(8):3376-88. PubMed ID: 20297846
[TBL] [Abstract][Full Text] [Related]
28. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
[TBL] [Abstract][Full Text] [Related]
29. The two human CXCR4 isoforms display different HIV receptor activities: consequences for the emergence of X4 strains.
Duquenne C; Psomas C; Gimenez S; Guigues A; Carles MJ; Barbuat C; Lavigne JP; Sotto A; Reynes J; Guglielmi P; Mettling C; François V; Corbeau P
J Immunol; 2014 Oct; 193(8):4188-94. PubMed ID: 25230750
[TBL] [Abstract][Full Text] [Related]
30. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
[TBL] [Abstract][Full Text] [Related]
31. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.
Fricker SP; Anastassov V; Cox J; Darkes MC; Grujic O; Idzan SR; Labrecque J; Lau G; Mosi RM; Nelson KL; Qin L; Santucci Z; Wong RS
Biochem Pharmacol; 2006 Aug; 72(5):588-96. PubMed ID: 16815309
[TBL] [Abstract][Full Text] [Related]
33. Restricted entry of R5 HIV Type 1 strains into eosinophilic cells.
Taylor RJ; Schols D; Wooley DP
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1244-53. PubMed ID: 15588346
[TBL] [Abstract][Full Text] [Related]
34. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
[TBL] [Abstract][Full Text] [Related]
35. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
[TBL] [Abstract][Full Text] [Related]
36. CXCL12/CXCR4 signaling induced itch and pain sensation in a murine model of allergic contact dermatitis.
Su W; Yu J; Liu Q; Ma L; Huang Y
Mol Pain; 2020; 16():1744806920926426. PubMed ID: 32418467
[TBL] [Abstract][Full Text] [Related]
37. Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
Armand-Ugón M; Quiñones-Mateu ME; Gutiérez A; Barretina J; Blanco J; Schols D; De Clercq E; Clotet B; Esté JA
Antivir Ther; 2003 Feb; 8(1):1-8. PubMed ID: 12713058
[TBL] [Abstract][Full Text] [Related]
38. Topical Application of S1P
Kang J; Lee JH; Im DS
Biomol Ther (Seoul); 2020 Nov; 28(6):537-541. PubMed ID: 32487782
[TBL] [Abstract][Full Text] [Related]
39. Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist.
Schols D
Verh K Acad Geneeskd Belg; 1999; 61(4):551-64. PubMed ID: 10500476
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
Fujii N; Nakashima H; Tamamura H
Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
